These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 25966350)

  • 1. Et and diabetic nephropathy: preclinical and clinical studies.
    Gagliardini E; Zoja C; Benigni A
    Semin Nephrol; 2015 Mar; 35(2):188-96. PubMed ID: 25966350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelin in diabetic renal disease.
    Benz K; Amann K
    Contrib Nephrol; 2011; 172():139-148. PubMed ID: 21893995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of the renin-angiotensin system in the pathogenesis, clinical picture and treatment of diabetic nephropathy].
    Wittmann I; Degrell P; Komáromy A; Molnár GA; Wagner Z; Wagner L; Mazák I; Nagy J
    Orv Hetil; 2003 Mar; 144(13):613-9. PubMed ID: 12728786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The endothelin system and endothelin receptor antagonists.
    Jandeleit-Dahm KA; Watson AM
    Curr Opin Nephrol Hypertens; 2012 Jan; 21(1):66-71. PubMed ID: 22123210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The renin-angiotensin system and diabetic nephropathy.
    Gurley SB; Coffman TM
    Semin Nephrol; 2007 Mar; 27(2):144-52. PubMed ID: 17418683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of loss of renal function over time in patients with diabetic nephropathy.
    Barnett A
    Am J Med; 2006 May; 119(5 Suppl 1):S40-7. PubMed ID: 16563947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of endothelin and endothelin receptor antagonists in renal disease.
    Neuhofer W; Pittrow D
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():78-88. PubMed ID: 16919017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of ET(A) receptor blockade increases renoprotection provided by renin-angiotensin system blockade in 5/6 nephrectomized Ren-2 transgenic rats.
    Čertíková Chábová V; Vernerová Z; Kujal P; Husková Z; Škaroupková P; Tesař V; Kramer HJ; Kompanowska-Jezierska E; Walkowska A; Sadowski J; Červenka L; Vaněčková I
    Life Sci; 2014 Nov; 118(2):297-305. PubMed ID: 24373834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathy.
    Thallas-Bonke V; Coughlan MT; Bach LA; Cooper ME; Forbes JM
    Am J Nephrol; 2010; 32(1):73-82. PubMed ID: 20551625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing antihypertensive therapy in patients with diabetic nephropathy.
    Ritz E; Rychlík I; Miltenberger-Miltenyi G
    J Hypertens Suppl; 1998 Sep; 16(7):S17-22. PubMed ID: 9855027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging therapeutic strategies in diabetic nephropathy.
    Ravera M; Re M; Weiss U; Deferrari L; Deferrari G
    J Nephrol; 2007; 20 Suppl 12():S23-32. PubMed ID: 18050139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
    Barnett AH; Bain SC; Bouter P; Karlberg B; Madsbad S; Jervell J; Mustonen J;
    N Engl J Med; 2004 Nov; 351(19):1952-61. PubMed ID: 15516696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
    De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
    Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal protective effect of YM598, a selective endothelin ET(A) receptor antagonist, against diabetic nephropathy in OLETF rats.
    Sugimoto K; Tsuruoka S; Fujimura A
    Eur J Pharmacol; 2002 Aug; 450(2):183-9. PubMed ID: 12206857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Research on renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression.
    Benigni A; Perico N; Remuzzi G
    Curr Opin Nephrol Hypertens; 2001 Jan; 10(1):1-6. PubMed ID: 11195041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelin antagonists for diabetic and non-diabetic chronic kidney disease.
    Kohan DE; Pollock DM
    Br J Clin Pharmacol; 2013 Oct; 76(4):573-9. PubMed ID: 23228194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelin and tubulointerstitial renal disease.
    Ong AC; von Websky K; Hocher B
    Semin Nephrol; 2015 Mar; 35(2):197-207. PubMed ID: 25966351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The renin-angiotensin-aldosterone system and its blockade in diabetic nephropathy: main focus on the role of aldosterone.
    Schjoedt KJ
    Dan Med Bull; 2011 Apr; 58(4):B4265. PubMed ID: 21466768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.